Gupta R K, Taylor D N, Bryla D A, Robbins J B, Szu S C
Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-2720, USA.
Infect Immun. 1998 Jul;66(7):3095-9. doi: 10.1128/IAI.66.7.3095-3099.1998.
Conjugate vaccines were prepared by binding hydrazine-treated lipopolysaccharide (DeALPS) from Vibrio cholerae O1, serotype Inaba, to cholera toxin (CT) variants CT-1 and CT-2. Volunteers (n = 75) were injected with either 25 microg of DeALPS, alone or as a conjugate, or the licensed cellular vaccine containing 4 x 10(9) organisms each of serotypes Inaba and Ogawa per ml. No serious adverse reactions were observed. DeALPS alone did not elicit serum LPS or vibriocidal antibodies in mice and only low levels of immunoglobulin M (IgM) anti-LPS in the volunteers. Recipients of the cellular vaccine had the highest IgM anti-LPS levels, but the difference was not statistically significant from that elicited by the conjugates. The conjugates elicited the highest levels of IgG anti-LPS (DeALPS-CT-2 > DeALPS-CT-1 > cellular vaccine). Both conjugates and the cellular vaccine elicited vibriocidal antibodies: after 8 months, recipients of cellular vaccine had the highest geometric mean titer (1,249), followed by DeALPS-CT-2 (588) and DeALPS-CT-1 (330). The correlation coefficient between IgG anti-LPS and 2-mercaptoethanol (2-ME)-resistant vibriocidal antibodies was 0. 81 (P = 0.0004). Convalescent sera from cholera patients had a mean vibriocidal titer of 2,525 that was removed by treatment with 2-ME. The vibriocidal activities of sera from all vaccine groups and from the patients were absorbed (>75%) by LPS but not by either CT-1 or CT-2. Conjugate-induced IgG vibriocidal antibodies persisted longer than those elicited by the whole-cell vaccine. Both conjugates, but not the cellular vaccine, elicited IgG anti-CT.
结合疫苗是通过将霍乱弧菌O1群、稻叶型血清型经肼处理的脂多糖(DeALPS)与霍乱毒素(CT)变体CT-1和CT-2结合制备而成。75名志愿者分别注射25微克单独的DeALPS、结合疫苗或每毫升含4×10⁹个稻叶型和小川型菌株的许可细胞疫苗。未观察到严重不良反应。单独的DeALPS在小鼠中未引发血清LPS或杀弧菌抗体,在志愿者中仅引发低水平的免疫球蛋白M(IgM)抗LPS抗体。细胞疫苗接种者的IgM抗LPS水平最高,但与结合疫苗引发的水平差异无统计学意义。结合疫苗引发的IgG抗LPS水平最高(DeALPS-CT-2>DeALPS-CT-1>细胞疫苗)。结合疫苗和细胞疫苗均引发杀弧菌抗体:8个月后,细胞疫苗接种者的几何平均滴度最高(1249),其次是DeALPS-CT-2(588)和DeALPS-CT-1(330)。IgG抗LPS与2-巯基乙醇(2-ME)抗性杀弧菌抗体之间的相关系数为0.81(P = 0.0004)。霍乱患者的恢复期血清杀弧菌平均滴度为2525,经2-ME处理后可消除。所有疫苗组和患者血清的杀弧菌活性均被LPS吸收(>75%),但未被CT-1或CT-2吸收。结合疫苗诱导的IgG杀弧菌抗体比全细胞疫苗诱导的持续时间更长。两种结合疫苗均引发IgG抗CT,但细胞疫苗未引发。